Liquid biopsy has been established as a powerful, minimally invasive, tool to detect clinically
actionable aberrations across numerous cancer types in real-time. With the development of …

Prostate cancer (PCa) incidence is increasing and endangers men's lives. Early detection of
PCa could improve overall survival (OS) by preventing metastasis. The prostate-specific …

Purpose: Androgen receptor pathway inhibitors (ARPI) are standard of care for treatment-
naïve metastatic castration-resistant prostate cancer (mCRPC), but rapid resistance is …

Background Treatment of poor prognosis metastatic castration-resistant prostate cancer
(mCRPC) includes taxane chemotherapy and androgen receptor pathway inhibitors (ARPI) …

Despite advances in the screening and treatment of prostate cancer, the therapy options
available, particularly for later stages of the disease, remain limited, and the treatment …

Plasma circulating tumor DNA (ctDNA) represents short fragments of tumor-derived DNA
released into the bloodstream primarily from cancer cells undergoing apoptosis. In …

Background Plasma tumor DNA fraction is prognostic in metastatic cancers. This could
improve risk stratification before commencing a new treatment. We hypothesized that a …

Epigenetic alterations, including changes in DNA methylation, histone modifications and
nucleosome remodeling, result in abnormal gene expression patterns that contribute to …

Over the years, an increasing proportion of metastatic prostate cancer patients has been
found to experience an initial bone flare phenomenon under both standard therapies …

Simple Summary Circulating tumor DNA (ctDNA) is a non-invasive method of identifying and
monitoring genitourinary cancers, including prostate, bladder, and renal cell carcinoma, via …